Acella to begin development of generic Bromfed DM

Acella Pharmaceuticals was recently approved to begin the development of a generic form of a sugar-free Bromfed DM cough syrup.
"We view Acella as an important niche company that works diligently to provide purposeful healthcare solutions, with value at the forefront of our corporate mission," Acella CEO Art Deas said. "This latest approval of a sugar-free, bioequivalent to Bromfed DM cough syrup is timely as we enter cough-cold season, when patients are most in need of cost-effective options."
Bromfed contains brompeniramine maleate, pseudophedrine hydrochloride and dextromethorphan hydrobromide, all of which is combined for the temporary relief of the symptoms brought on by the common cold, the flu, allergies or other illnesses that affect breathing.
"Having a sugar-free, bioequivalent to Bromfed DM cough syrup supports our strategy of providing pharmaceutical drugs to all of our customers," Acella Head of Research and Development Allen Fields said. "We are excited about our other, affordable products currently under review with the U.S. Food and Drug Administration, in fulfillment of our mission to patients and managed care."